Latent Labs Secures $50M to Revolutionize Protein Design with AI

Founded by a DeepMind alumnus, the startup aims to leverage generative AI to create new therapeutic proteins and accelerate drug discovery.

Latent Labs, founded by former DeepMind scientist Simon Kohl, has raised $50 million to develop AI models for designing novel proteins.
The startup's technology seeks to move drug discovery into the computational realm, reducing reliance on traditional wet lab experiments.
Latent Labs plans to collaborate with biotech and pharmaceutical companies to create custom therapeutic molecules tailored to specific diseases.
The company employs 15 staff across London and San Francisco, including former DeepMind researchers and experts in protein design.
Investors, including Radical Ventures, Sofinnova Partners, and notable angel backers, see significant potential in Latent Labs' ability to transform drug development.